Ultrasensitive and scalable biomarker detection in blood
Accurately quantify protein biomarkers with best-in-class sensitivity and a flexible workflow.
Superior performance
with a simple, cost-effective workflow
Accurate quantification of protein biomarkers is essential for early diagnosis, effective patient stratification in clinical trials, and efficient clinical research aimed at tackling Alzheimer’s disease (AD). However, gold standard tests often depend on complex, invasive, and costly technologies. A reliable blood-based biomarker test with precise and sensitive quantification capabilities will accelerate breakthroughs, facilitate the development of therapeutics, and significantly improve outcomes.
Taudia is revolutionizing Alzheimer’s disease (AD) diagnostics with a rapid, cost-effective, and fully automated sample-to-answer solution. Our proprietary technology integrates ultrasensitive, accurate quantification with an efficient workflow, delivering results in under four hours. By combining simplicity, flexibility, and scalability, our platform empowers researchers and clinicians to advance AD treatment and enhance patient care.
Go from sample to answer in three hours
Easily accessible blood samples
FDA Class II sample to answer benchtop instrument
Throughput flexibility; test 16, 32, or 48 samples/run
Precise and accurate results
Best-in-class sensitivity
Lower cost per sample when compared to competing systems
Easily accessible blood samples
FDA Class II sample to answer benchtop instrument
Throughput flexibility; test 16, 32, or 48 samples/run
Precise and accurate results
Best-in-class sensitivity
Lower cost per sample when compared to competing systems
Accelerate therapeutic development
- Validate novel biomarkers with ultrasensitivity
- Recruit and stratify patients for clinical trials
- Monitor therapeutic response using biomarker quantitation
- Develop sensitive companion diagnostic assays
Remove barriers to access
- Eliminate reliance on costly infrastructure
- Require only small volume of blood samples
- Measure multiple targets with a single test
- Adapt seamlessly to throughput needs
Improving sensitivity without increasing cost or sacrificing flexibility
We combine innovative dual-conjugated antibody probes with a fully automated, sample-to-answer system to deliver precise, hands-free protein biomarker quantitation in blood or other complex matrices – all in under four hours.
The simplicity of our technology offers unmatched versatility, supporting everything from benchtop testing with a pipettor (similar to traditional ELISA) to high-throughput analysis of hundreds of samples per day. Taudia empowers users with ultrasensitive protein quantification, without added complexity or cost.
Who we are
At Taudia, we’re committed to delivering ultra-sensitive, reliable, and scalable solutions for protein biomarker detection to accelerate therapeutic development, enhance biomarker validation, and enable early diagnosis.